Shares of Roivant (ROIV - Free Report) rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche (RHHBY - Free Report) was close to buying ROIV’s inflammatory bowel disease (IBD) candidate, RVT-3101, for more than $7 billion.
RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody, is being developed in mid-stage studies for ulcerative colitis and Crohn’s disease. In the TUSCANY-2 phase IIb study in ulcerative colitis, RVT-3101 led to improved efficacy data from the induction period at week 14 to the chronic period at week 56. RVT-3101 was well tolerated in the study, with a favorable safety profile across all doses.
The data, announced last month, outperformed the company’s expectations. Roivant believes the data, if confirmed in phase III studies, has the potential to transform the treatment paradigm for IBD patients. Inflammatory bowel disease is an approximately $17 billion market in the United States alone and growing. Leading therapies generated more than $15 billion in U.S. sales in 2022.
Roivant is also conducting a phase IIb study in Crohn’s disease, the top-line data from which is expected to be released in the fourth quarter of 2024.
Roivant’s stock has risen 45.2% this year so far against a decrease of 10.1% for the industry.
The WSJ article mentioned that Roivant could announce the sale of the IBD drug to Roche “in the coming days.”
Roivant is developing RVT-3101 in partnership with Pfizer (PFE - Free Report) through a subsidiary called Telavant. Roivant also has another subsidiary with Pfizer called Priovant Therapeutics, which makes novel therapies for autoimmune diseases. Priovant Therapeutics’ lead compound, brepocitinib is being developed in a phase III study for the treatment of dermatomyositis.
Zacks Rank
Roivant currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Shares of Roivant (ROIV - Free Report) rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche (RHHBY - Free Report) was close to buying ROIV’s inflammatory bowel disease (IBD) candidate, RVT-3101, for more than $7 billion.
RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody, is being developed in mid-stage studies for ulcerative colitis and Crohn’s disease. In the TUSCANY-2 phase IIb study in ulcerative colitis, RVT-3101 led to improved efficacy data from the induction period at week 14 to the chronic period at week 56. RVT-3101 was well tolerated in the study, with a favorable safety profile across all doses.
The data, announced last month, outperformed the company’s expectations. Roivant believes the data, if confirmed in phase III studies, has the potential to transform the treatment paradigm for IBD patients. Inflammatory bowel disease is an approximately $17 billion market in the United States alone and growing. Leading therapies generated more than $15 billion in U.S. sales in 2022.
Roivant is also conducting a phase IIb study in Crohn’s disease, the top-line data from which is expected to be released in the fourth quarter of 2024.
Roivant’s stock has risen 45.2% this year so far against a decrease of 10.1% for the industry.
The WSJ article mentioned that Roivant could announce the sale of the IBD drug to Roche “in the coming days.”
Roivant is developing RVT-3101 in partnership with Pfizer (PFE - Free Report) through a subsidiary called Telavant. Roivant also has another subsidiary with Pfizer called Priovant Therapeutics, which makes novel therapies for autoimmune diseases. Priovant Therapeutics’ lead compound, brepocitinib is being developed in a phase III study for the treatment of dermatomyositis.
Zacks Rank
Roivant currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on RHHBY - FREE
Get the latest research report on PFE - FREE
Get the latest research report on ROIV - FREE